Harrow Health Overview - Harrow Health, Inc. is a publicly traded pharmaceutical company (Nasdaq:HROW) based in Nashville, TN. - Harrow Health started six healthcare businesses since 2014, including ImprimisRx, Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. - Harrow Health hired Drew Livingston as its Chief Innovation Officer in 2019. - Harrow Health's subsidiary, Visionology.com, focuses on telemedicine. - Harrow Health is known for its advocacy for drug pricing and patient access to affordable medication.

Administration and Drug Pricing Advocacy - Mark L. Baum is the founder and CEO of Harrow Health, with a background in law. - Baum has been working in the HIV-related pharmacy field since 1999. - Baum has been an advocate for drug pricing and patient advocacy, including debating former US congressman James Greenwood on this issue. - Harrow Health, through its ImprimisRx subsidiary, aims to create competition for monopolised drugs by marketing new formulations as a compounding pharmacy. - Harrow Health gained attention for offering low-cost alternatives to expensive medications, such as a $1 per pill alternative to Daraprim.

ImprimisRx Compounding Business - ImprimisRx is Harrow Health's compounding subsidiary. - ImprimisRx was the first compounding company to offer cGMP ophthalmic eye drops and other sterile compounded products at a national scale. - ImprimisRx's primary business is compounding drugs to market them to specific populations. - ImprimisRx focuses on developing and selling inexpensive alternatives to off-patent medicines. - ImprimisRx expanded its business to include the sale of FDA-approved steroid product called Dexycu through a partnership with EyePoint Pharmaceuticals.

Litigation - Harrow Health (then Imprimis Pharmaceuticals) faced a lawsuit from Allergan for alleged false and misleading marketing statements. - Allergan was accused of engaging in significant lobbying to complain about ImprimisRx. - In 2017, ImprimisRx received a warning letter from the FDA regarding false or misleading claims about efficacy and risks in their eye drops. - After a jury trial, Harrow was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan seeking $60 million. - The lawsuit highlighted the power dynamics between a small pharmaceutical company like Imprimis and a large company like Allergan.

External Links and References - Harrow Health's accomplishments and activities have been covered by various news outlets, including The Wall Street Journal, Forbes, and USA TODAY. - ImprimisRx's low-cost alternatives to expensive drugs gained international attention. - Harrow Health's CEO, Mark L. Baum, has written about drug pricing and monopolies in his monograph and has spoken at the Oxford Union debating society. - Harrow Health's subsidiaries, Eton Pharmaceuticals and Surface Pharmaceuticals, have received significant funding for their operations. - Harrow Health's Visionology.com subsidiary focuses on telemedicine and improving access to healthcare services.